Cancer Journey


VIDEOS

ARTICLES

Should We Continue the EGFR Inhibitor When We Start Chemo for Acquired Resistance?

Here's the typical scenario for someone with an EGFR mutation who has a good response to an EGFR tyrosine kinase inhibitor (TKI). After a year or so...

Early Data on Acquired Resistance to Targeted Therapies: Start Local Therapy, Continue the Targeted Therapy?

Earlier this week, I provided a brief review of several highlighted posters at ASCO, along with some commentary to place them into context. These...

Top 5 Notable Abstracts in the Small Cell Lung Cancer and Stage I-III NSCLC Track

Here are the 5 presentations at ASCO in stage I-III NSCLC and small cell lung cancer that I think are most interesting and relevant. You'll note that...

My Top 5 Notable ASCO 2012 Abstracts in Metastatic NSCLC

The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big...

Modifying Factors: Should Patients with Smaller Resected Node-Negative NSCLC Tumors Receive Adjuvant Chemo?

While post-operative chemotherapy for early stage NSCLC is a well-established standard for relatively healthy patients with stage II or higher...

ONLINE COMMUNITY

RECENT POSTS

Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Thank you very much Jim and
Last Comment by semone12 on Oct 24, 2018 1:19 pm
Stage IIIb ALK NSCLC first line treatment
Thank you for your answer!
Last Comment by Jim C GRACE Co… on Nov 1, 2018 5:55 am
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Last Comment by semone12 on Oct 24, 2018 1:19 pm
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Thank you Janine! I
Last Comment by semone12 on Oct 24, 2018 1:19 pm
Keytruda for Adenocarcinoma (NSCLC), first PET-CT result
Hi Simone,
Last Comment by semone12 on Oct 24, 2018 1:19 pm

Dr. Ravi Salgia on Management Strategies for Acquired Resistance to Targeted Therapies, Single Focus or More Diffuse

Article

Dr. Ravi Salgia from University of Chicago explains his approach to management of acquired resistance to a targeted therapy for advanced NSCLC, both in the setting of a single area of progression and also when disease progression is more diffuse.

[powerpress]

Dr. Alan Sandler: Is There a Danger that the Latest Advances in Molecular Testing Are Only Available in Limited Specialty Settings?

Article

Dr. Alan Sandler, Oregon Health and Science University, describes how he sees very specialized molecular testing for lung cancer becoming increasingly available to oncologists seeing patients in the community setting.

[powerpress]

Dr. Bob Doebele: Will We Be Able to Use Molecular Markers and Apply Targeted Therapies to Broader Lung Cancer Subtypes in the Near Future?

Article

Dr. Bob Doebele from the University of Colorado offers his perspective on whether targeted therapies will be able to applied to broader populations of patients with advanced NSCLC than those primarily with minimal smoking histories and an adenocarcinoma.

[powerpress]

Drs. Ross Camidge and Corey Langer: Who Do You Recommend Repeat Biopsy for if There Isn’t Enough Tissue for Molecular Testing?

Article

Drs. Ross Camidge and Corey Langer discuss which patients with advanced NSCLC they would recommend should have a repeat biopsy if their initial tissue sample doesn't have sufficient tissue for molecular testing.

[powerpress]

Dr. Heather Wakelee: How Should We Use Molecular Marker Information for Management of Earlier Stage Non-Small Cell Lung Cancer?

Article

Dr. Heather Wakelee from Stanford University discusses the open question of whether patients with resectable or locally advanced NSCLC should have testing for molecular markers, as well as how we might use this information in clinical practice.

 [powerpress]

Subscribe to Lung Cancer